Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes.

Cohort studyClinical lymphoma, myeloma & leukemia· Jun 2026

Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes.

Samuel Ramos, Shin Zaw, Allison Carilli, Ishak A Mansi

Read paper

EndocrinologyCohort studyQ2IF 2.7

GLP-1RA use was not associated with altered Hodgkin's lymphoma odds.

Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes.

Samuel Ramos … Ishak A Mansi

Clinical lymphoma, myeloma & leukemia · Jun 2026

Background

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely used for the management of diabetes mellitus and obesity.

Methods

We conducted a retrospective cohort study using the Veterans Affairs (Veterans Affairs) national data, including patients with diabetes initiating GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP-4i), as active comparators, during years 2006 to 2021.

n = 100,038 matched pairs

Results

GLP-1RA users had slightly lower odds of Hodgkin's lymphoma than DPP-4i users

OR 0.89 (95% CI 0.55 to 1.43)

null 1

0.55

1.43

CI crosses the null - not significant

More results

Findings were consistent across most subgroup analyses by duration of therapy, baseline body mass index, and weight change.

“

Conclusion

In this large national cohort of veterans with diabetes, GLP-1RA use was not associated with an increased or decreased risk of hematologic malignancies compared to DPP-4i.

Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes.

Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes.

Related papers